Sign up for Table of Contents Alerts.
Email this page
Print this page
Brief Report
Inhibition of Paclitaxel-Induced Proteasome Activation Influences Paclitaxel Cytotoxicity in Breast Cancer Cells in a Sequence-Dependent Manner
Héctor Hernández-Vargas, Cayetano von Kobbe, Carolina Sánchez-Estévez, Mercedes Julián-Tendero, José Palacios and Gema Moreno-Bueno
volume 6 | issue 21
1 November 2007Pages: 2662 - 2668
Subscribe to this journal for $129/year
Although the anti-tumour effects of paclitaxel result mainly from mitotic arrest, recent evidences suggest alternative mechanisms of cytotoxicity. Cell cycle, cell death, and gene expression assays were used to understand the molecular mechanisms of paclitaxel cytotoxicity in breast cancer cells. G2/M cell cycle arrest and cell death coincided with the regulation of genes involved in cell death, cell cycle control, microtubule-based processes, oxidative stress, and ubiquitin-proteasome system. Induction of proteasome genes was also correlated with an accumulation of protein for proteasome subunits. Furthermore, a schedule-dependent regulation of paclitaxel-induced cytotoxicity was observed after combining paclitaxel and the proteasome inhibitor MG132. Proteasome inhibition after paclitaxel exposure induced the highest rate of growth inhibition and apoptosis, with no effect on mitotic arrest. These findings give support to clinical combinations of taxanes with proteasome inhibitors, outlining the importance of considering the sequence when designing such regimens.
Authors
Héctor Hernández-Vargas
Spanish National Cancer Centre; Madrid, Spain
Cayetano von Kobbe
Spanish National Cancer Centre (CNIO); Madrid, Spain
Carolina Sánchez-Estévez
Spanish National Cancer Centre (CNIO); Madrid, Spain
Mercedes Julián-Tendero
Spanish National Cancer Centre (CNIO); Madrid, Spain
José Palacios
Spanish National Cancer Centre (CNIO); Madrid, Spain
Gema Moreno-Bueno
Instituto de Investigaciones Biomedicas Alberto Sols; Madrid, Spain




